TABLE 4.

Activity of benzimidazole ribonucleosides on drug-resistant isolates of HCMV

Isolate50% inhibitory concn (μM)a
BDCRB1263W94 (37°C)1263W94 (34°C)175XGCV/PFA
C8805/37-1-11.4 ± 1.4>27152.8 ± 0.8100 ± 56
759rD1000.4 ± 0.23.3 ± 0.62.12.1 ± 0.1113 ± 62
GDGrP532.1 ± 1.037 ± 28.52.9 ± 0.562.8 ± 27
C8706/13-1-11.3 ± 1.10.3 ± 0.20.82.1 ± 0.422 ± 10
C9209/1-4-41.5 ± 1.01.0 ± 00.13.5 ± 098 ± 34
C8914-63.3 ± 0.424 ± 240.610 ± 2.8104 ± 77
VR4760R1.7 ± 1.50.5 ± 0.3<0.082.5 ± 1.5830 ± 28b
VR4955R2.8 ± 0.30.7 ± 0.030.23.5 ± 0700 ± 183b
1117R2.8 ± 050 ± 50.43.5 ± 1.042 ± 2.2
RCMP971.085NTc2.335
  • a Values are expressed as the mean ± standard deviation of at least two plaque reduction assays.

  • b Control drug for these strains is PFA.

  • c NT, not tested.